ADAPTATION OF [¹⁸F]PSMA-1007 RADIOSYNTHESIS TECHNOLOGY AND QUALITY CONTROL IN A CLINICAL CENTER OF THE ABAI REGION

Radiopharmaceuticals based on ligands targeting the prostate-specific membrane antigen (PSMA) are recognized as the “gold standard” for prostate cancer (PCa) imaging using positron emission tomography (PET). This study presents, for the first time in the Republic of Kazakhstan, the results of adapting an automated one-step radiosynthesis technology and performing a comprehensive quality assessment of the [¹⁸F]PSMA-1007 radiopharmaceutical at the Center for Nuclear Medicine and Oncology (Semey, Abai Region). During the study, the direct nucleophilic radiofluorination protocol was optimized, resulting in a stable radiochemical yield (mean 48%) while reducing the total synthesis time to 35–40 minutes. A full quality control cycle confirmed complete compliance of the final product with the European Pharmacopoeia specifications, including radiochemical purity (97–98%), sterility, and apyrogenicity. The successful implementation of this project represents a strategic milestone in the development of nuclear medicine in Kazakhstan. The validated stability and quality parameters of [¹⁸F]PSMA-1007 provide a scientific and methodological basis for scaling up hightechnology production at future cyclotron facilities across the country. The introduction of this radiopharmaceutical into clinical practice significantly improves the accuracy of prostate cancer staging and recurrence detection in Kazakhstan in accordance with international standards.

1. Global Cancer Observatory: Cancer Today (GLOBOCAN 2022). - Lyon : International Agency for Research on Cancer, 2024. URL: https://gco.iarc.who.int/today

2. Albers P., Franiel T., Kötter T., Kristiansen G., Herrmann K., Wiegel T.. The Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift. // Dtsch Arztebl Int. - 2025. - Vol.122, No. 15 - P. 420- 426. - https://doi.org/10.3238/arztebl.m2025.0099

3. Mottet N., van den Bergh R.C.N., Briers E., Van den Broeck T., Cumberbatch M.G., De Santis M. et al. EauEanm-Estro-Esur-Siog guidelines on prostate cancer - 2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent // Eur Urol. - 2021. - Vol. 79, No. 2. - P. 243-262. - https://doi.org/10.1016/j.eururo.2020.09.042

4. Tan Y., Fang Z., Tang Y., Liu K., Zhao H. Clinical advancement of precision theranostics in prostate cancer // Front Oncol. - 2023. - Vol. 13. - https://doi.org/10.3389/fonc.2023.1072510

5. Lau J., Rousseau E., Kwon D., Lin K.S., Benard F., Chen X. Insight into the development of PET radiopharmaceuticals for oncology // Cancers (Basel). - 2020. - Vol. 12, No. 5. - P. 1312. - https://doi.org/10.3390/cancers120513126.

6. Oprea-Lager D., MacLennan S., Bjartell A., Briganti A., Burger I., de Jong I. et al. European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer // Eur Urol. - 2024. - Vol. 85. - P. 49-60. - https://doi.org/10.1016/j.eururo.2023.09.003

7. Capasso G., Stefanucci A., Tolomeo A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy // Eur J Med Chem. - 2024. - Vol. 263. - P. 115966. - https://doi.org/10.1016/j.ejmech.2023.115966

8. Armany D., Vo L., Self D., Baskaranathan S., Hossack T., Bariol S. et al. The role of 18F-PSMA-1007 PET/CT in the staging and detection of recurrence of prostate cancer: a scoping review // Cancers (Basel). - 2025. - Vol. 17, No. 6. - P. 1049. - https://doi.org/10.3390/cancers17061049

9. Hong J.J., Liu B.L., Wang Z.Q., Tang K., Ji X.W., Yin W.W., Lin J., Zheng X.W. The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer // EJNMMI Res. - 2020. - Vol. 10, No. 1. - P. 138. - https://doi.org/10.1186/s13550-020-00730-1

10. Kim S.B., Song I.H., Kim S.Y., Ko H.Y., Kil H.S., Chi D.Y. et al. Preclinical evaluation of a companion diagnostic radiopharmaceutical [18F]PSMA-1007 in a subcutaneous prostate cancer xenograft mouse model // Mol Pharm. - 2022. - Vol. 20, No. 2. - P. 1050-1060. - https://doi.org/10.1021/acs.molpharmaceut.2c00788

11. Abdel-Wahab M., Giammarile F., Carrara M., Paez D., Hricak H., Ayati H. et al. Radiotherapy and theranostics: a Lancet Oncology Commission // Lancet Oncol. - 2024. - Vol. 25, Suppl. 2. - https://doi.org/10.1016/S1470-2045(24)00407-8

12. Production and quality control of fluorine-18 labelled radiopharmaceuticals. - Vienna: International Atomic Energy Agency, 2021. - (IAEA TECDOC No. 1968).

13. Quality control in the production of radiopharmaceuticals. - Vienna: International Atomic Energy Agency, 2018. - (IAEA TECDOC No. 1856).

14. Oliveira A.P., Castro A.C.F., Costa C.L.S. et al. Development and validation of methods to evaluate the chemical purity, radiochemical purity, and residual solvents of the automated synthesis of [18F]PSMA-1007 // Microchem J. - 2025. - Vol. 213. - P. 113874. - https://doi.org/10.1016/j.microc.2025.113874

15. European Pharmacopoeia. PSMA-1007 (18F) Injection (Monograph No. 07/2021:3116). - 10th ed. - Strasbourg: EDQM, 2020. - URL: https://www.edqm.eu